Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049719 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL274257 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL9644644 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL18699067 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL1538336 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL9646107 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL3048726 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL18675767 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL22408792 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 | |
| SCHEMBL600341 | 1.00 | ALDH1A1 (0.38) | ALDH1A1CYP3A4TSHRCDC25ALPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033335-A1 | METHOD FOR PRODUCING DIVINYL ETHER COMPOUND HAVING ALKYLENE SKELETON | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20220033334-A1 | METHOD FOR PRODUCING DIVINYL ETHER COMPOUND HAVING ALKYLENE SKELETON | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3889125-A1 | METHOD FOR PRODUCING DIVINYL ETHER COMPOUND HAVING ALKYLENE SKELETON | Maruzen Petrochemical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3889126-A1 | METHOD FOR PRODUCING DIVINYL ETHER COMPOUND HAVING ALKYLENE SKELETON | Maruzen Petrochemical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166016-A | Method for producing divinyl ether compound having alkylene skeleton | 丸善石油化学株式会社 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166015-A | Method for producing divinyl ether compound having alkylene skeleton | 丸善石油化学株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2019025398-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-20180143546-A1 | METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-05-24 | — | — | US | disclosed |
| US-9971268-B2 | Curable liquid developer having a cationically polymerizable liquid monomer with a monofunctional vinyl ether compound | CANON KABUSHIKI KAISHA (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-3151067-A1 | CURABLE LIQUID DEVELOPER | Canon Kabushiki Kaisha (JP) | 2017-04-05 | — | — | EP | disclosed |
| CN-101466747-B | Process for production of polyradical compound and battery cell | NIPPON ELECTRIC CO | 2011-09-28 | — | — | CN | disclosed |
| US-20100255372-A1 | PROCESS FOR PRODUCING POLYRADICAL COMPOUND AND BATTERY CELL | NEC CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| CN-101466747-A | Process for production of polyradical compound and battery cell | NIPPON ELECTRIC CO (JP) | 2009-06-24 | — | — | CN | disclosed |
| EP-2025689-A1 | PROCESS FOR PRODUCTION OF POLYRADICAL COMPOUND AND BATTERY CELL | NEC Corporation (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1223161-A2 | Method to stabilise and/or lower the color number of alkenyl compounds | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-17 | — | — | EP | disclosed |
| US-20020091254-A1 | Stabilizing and/or lowering the color number of alkenyl compounds | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | US | disclosed |
| US-6384216-B1 | CARRYING OUT TWO DISTILLATIONS IN WHICH THE PURIFIED ALKENYL COMPOUNDS OBTAINED FROM GAS PHASE BY CONDENSATION, WHERE THE TIME BETWEEN FIRST DISTILLATION AFTER SYNTHESIS OF ALKENYL COMPOUNDS AND FURTHER DISTILLATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-07 | — | — | US | disclosed |
| US-20020038059-A1 | PURIFICATION OF ALKENYL COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | US | disclosed |
| US-5147727-A | Aryloxy polyvinyl ethers | ISP INVESTMENTS INC. (US) | 1992-09-15 | — | — | US | disclosed |
| US-5082874-A | Aryloxy polyvinyl ethers | ISP INVESTMENTS INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033334-A1 | METHOD FOR PRODUCING DIVINYL ETHER COMPOUND HAVING ALKYLENE SKELETON | DECR2, KAT8, DECR1 | ALDH1A1 2263/4885CYP3A4 195/4885TSHR 3684/4885 |
| US-20220033335-A1 | METHOD FOR PRODUCING DIVINYL ETHER COMPOUND HAVING ALKYLENE SKELETON | DECR2, DECR1, ACMSD | ALDH1A1 1072/4885CYP3A4 140/4885TSHR 3362/4885 |
| US-20020091254-A1 | Stabilizing and/or lowering the color number of alkenyl compounds | SOD1, NOX4, CAT | ALDH1A1 462/4885CYP3A4 764/4885TSHR 4454/4885 |
| US-20020038059-A1 | PURIFICATION OF ALKENYL COMPOUNDS | TPR, AGPAT5, PCNA | ALDH1A1 1108/4885CYP3A4 1391/4885TSHR 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.